

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 August 2003 (14.08.2003)

PCT

(10) International Publication Number
WO 03/066030 A2

- (51) International Patent Classification⁷: **A61K 9/34**
- (21) International Application Number: **PCT/US03/03837**
- (22) International Filing Date: **6 February 2003 (06.02.2003)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
60/355,705 **7 February 2002 (07.02.2002)** **US**
- (71) Applicant (*for all designated States except US*): **PHARMACIA CORPORATION [US/US]**; Global Patent Department, 575 Maryville Centre Drive - 5th Floor, Mail Zone 1006, St. Louis, MO 63141 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **MARTINO, Alice, C. [US/US]**; 6232 Far Hills Way, Kalamazoo, MI 49009 (US). **NOACK, Robert, M. [US/US]**; 1134 Iroquois Drive S.E., Grand Rapids, MI 49506 (US). **PIERMAN, Steven, A. [US/US]**; 7608 Harvest Lane, Portage, MI 49002 (US).
- (74) Agents: **FORBES, James, C. et al.**; Pharmacia Corporation, Global Patent Department, P.O. Box 1027, St. Louis, MO 63006 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/066030 A2

(54) Title: **PHARMACEUTICAL TABLET**

(57) Abstract: A pharmaceutical tablet is provide comprising a core and a coating adherent thereto, wherein (a) the core comprises solid particles of a water-soluble dye distributed in a matrix, and (b) the coating comprises gellan gum. The tablet is suitable for peroral or intraoral administration, for example for delivery of a drug contained in the core of the tablet to a subject. The tablet has a speckled appearance that renders the tablet readily identifiable.

BEST AVAILABLE COPY

PHARMACEUTICAL TABLET

FIELD OF THE INVENTION

The present invention relates to orally deliverable pharmaceutical dosage forms, more particularly tablets.

5 BACKGROUND OF THE INVENTION

Tablets are the most common and convenient pharmaceutical dosage form for oral administration of medications. It is an important functional attribute of a tablet that it be readily identifiable by appearance, including by size, shape, surface texture, markings and color. Such ready identifiability is important in minimizing dispensing errors and in enabling patients on multiple medication to distinguish among the drugs they take at different times or frequencies. A vast array of drugs are now formulated as tablets, many of these drugs being formulated at different dosage strengths, and it is therefore becoming ever more important, yet ever more difficult to insure, that any new tablet has unique appearance.

15 In particular, the range of readily distinguishable colors available to the formulator of tablets is rather limited. To some extent this problem has been alleviated by use of particolored, bicolored or multicolored tablets. However, a need remains in the art for tablets having unique surface color patterns.

In the case of coated tablets, color can be an attribute of the surface coating. For example, a range of opaque pigments are available for incorporation in tablet coating compositions such as those based on ethylcellulose; these pigments tend to impart a solid white or colored appearance to a coated tablet. Alternatively, the surface coating can be clear and transparent, and the color of the coated tablet is controlled by the color of the tablet core underlying the coating.

25 U.S. Patent No. 6,326,028 to Nivaggioli *et al.*, incorporated herein by reference, discloses a tablet coating comprising gellan gum. Such a coating is said to be useful for tablets to be taken orally, and to confer benefits in appearance, identification, mouth feel, reduced dust, stability, color and/or swallowability.

International Patent Publication No. WO 01/10406, incorporated herein by reference, discloses compositions said to be suitable for a wide range of routes of administration of sildenafil citrate, including buccal and sublingual routes. Preferred

compositions disclosed are said to comprise a solution, gel, semisolid, suspension, metered dose device, transdermal patch or film. It is indicated that such compositions can include a gelling system, for example gellan gum 0.5% to 10%.

International Patent Publication No. WO 02/05820, incorporated herein by
5 reference, discloses film dosage forms comprising sildenafil citrate. These dosage forms are prepared by mixing a solid dispersion of sildenafil citrate and a water-soluble sugar with a hydrocolloid and optionally other ingredients, and are said, upon placement on a mucosal surface, to form a coating that subsequently disintegrates and dissolves to release sildenafil. Gellan sodium salt is listed among hydrocolloids said to
10 be useful in such film dosage forms.

U.S. Patent No. 6,291,506 to Levin, incorporated herein by reference, discloses that the ophthalmic drug carvedilol can be formulated for ocular administration by suspending it in an agent such as gellan gum that will increase corneal contact time with the drug. Other possible delivery modes for the drug are contemplated therein. A
15 claim is included to a method wherein the drug is delivered by a selection of routes including sublingually.

SUMMARY OF THE INVENTION

There is now provided a pharmaceutical tablet comprising a core and a coating adherent thereto, wherein (a) the core comprises solid particles of a water-soluble dye
20 distributed in a matrix, and (b) the coating comprises gellan gum.

The tablet is particularly suitable for peroral or intraoral administration, for example for delivery of a drug contained in the core of the tablet to a subject, illustratively a human subject. The term "peroral" herein refers to administration via the mouth involving swallowing of the tablet without substantial prior disintegration of
25 the tablet in the mouth, so that absorption of the drug typically occurs in the gastrointestinal tract. The term "intraoral" herein refers to administration by placement of the tablet in the mouth of the subject, where the tablet disintegrates and/or dissolves, so that absorption of the drug typically occurs at least in part via the oral mucosa. For intraoral administration, the tablet can be placed in or on any part of the
30 mouth, but placement of the tablet in the sublingual or buccal spaces is preferred.

The tablet can alternatively be dissolved or dispersed in a liquid vehicle, preferably water, and swallowed as a draft.

Tablets of the invention have an unusual speckled appearance. Without being bound by theory, it is believed that during the process of coating the core with an aqueous coating composition comprising gellan gum, dye particles in contact with the coating composition partially dissolve, causing color to "bleed" into the coating at the locus of each such particle. The color then becomes fixed as the coating dries. The speckled pattern is accentuated and rendered even more attractive or elegant by a high gloss surface texture contributed by the gellan gum. As described more fully hereinbelow, many variants of the speckled pattern characteristic of tablets of the invention are possible and practicable, adding a new option to the formulator seeking to prepare a readily identifiable tablet.

As a further advantage, the speckled pattern of tablets of the invention can obscure any small areas of discoloration that can sometimes result from variation in process conditions.

Other features, advantages and benefits of the invention will be apparent from the description that follows.

DETAILED DESCRIPTION OF THE INVENTION

A tablet of the invention can be a placebo tablet, *i.e.*, containing no drug or other active agent in the core thereof. Preferably a tablet of the invention contains in the core a therapeutically and/or prophylactically useful amount of a drug, more preferably a drug that is advantageously delivered by peroral or intraoral administration.

For example, a drug present in the core of a tablet of the invention can be selected from the following illustrative classes: ACE inhibitors; α -adrenergic agonists; β -adrenergic agonists; α -adrenergic blockers; β -adrenergic blockers (beta blockers); alcohol deterrents; aldose reductase inhibitors; aldosterone antagonists; amino acids; anabolics; analgesics (both narcotic and non-narcotic); anesthetics; anorexics; antacids; anthelmintics; antiacne agents; antiallergics; antiandrogens; antianginal agents; antianxiety agents; antiarrhythmics; antiasthmatics; antibacterial agents and antibiotics; antialoppecia and antibaldness agents; antiamebics; antibodies; anticholinergic drugs; anticoagulants and blood thinners; anticolitis drugs; anticonvulsants; anticystitis drugs; antidepressants; antidiabetic agents; antidiarrheals; antidiuretics; antidotes; antiemetics; antiestrogens; antiflatulents; antifungal agents; antigens; antiglaucoma agents;

antihistaminics; antihyperactives; antihyperlipoproteinemics; antihypertensives;
antihyperthyroid agents; antihypotensives; antihypothyroid agents; anti-infectives; anti-
inflammatories (both steroidal and nonsteroidal); antimalarial agents; antimigraine
agents; antineoplastics; antiobesity agents; antiparkinsonian agents and antidyskinetics;
5 antipneumonia agents; antiprotozoal agents; antipruritics; antipsoriatics; antipsychotics;
antipyretics; antirheumatics; antisecretory agents; anti-shock medications;
antispasmodics; antithrombotics; antitumor agents; antitussives; antiulceratives;
antiviral agents; anxiolytics; bactericidins; bone densifiers; bronchodilators; calcium
channel blockers; carbonic anhydrase inhibitors; cardiotonics and heart stimulants;
10 chemotherapeutics; choleretics; cholinergics; chronic fatigue syndrome medications;
CNS stimulants; coagulants; contraceptives; cystic fibrosis medications; decongestants;
diuretics; dopamine receptor agonists; dopamine receptor antagonists; enzymes;
estrogens; expectorants; gastric hyperactivity medications; glucocorticoids;
hemostatics; HMG CoA reductase inhibitors; hormones; hypnotics;
15 immunomodulators; immunosuppressants; laxatives; medicaments for oral and
periodontal diseases; miotics; monoamine oxidase inhibitors; mucolytics; multiple
sclerosis medications; muscle relaxants; mydriatics; narcotic antagonists; NMDA
receptor antagonists; oligonucleotides; ophthalmic drugs; oxytocics; peptides,
polypeptides and proteins; polysaccharides; progestogens; prostaglandins; protease
20 inhibitors; respiratory stimulants; sedatives; serotonin uptake inhibitors; sex hormones
including androgens; smoking cessation drugs; smooth muscle relaxants; smooth
muscle stimulants; thrombolytics; tranquilizers; urinary acidifiers; urinary incontinence
medications; vasodilators; vasoprotectants; and combinations thereof.

It will be understood that any reference herein to a particular drug compound
25 includes tautomers, stereoisomers, salts and prodrugs of that compound and is not
specific to any one solid state form of the drug.

In one embodiment a drug contained in the core of the tablet is a smoking
cessation drug, for example nicotine, a nicotine metabolite or a non-nicotine aid to
smoking cessation such as bupropion or ibogaine.

30 Illustratively, a smoking cessation drug can be selected from nicotine and
metabolites thereof (e.g., cotinine, norcotinine, nornicotine, nicotine N-oxide, cotinine
N-oxide, 3-hydroxycotinine and 5-hydroxycotinine), ibogaine, bupropion and

metabolites thereof (*e.g.*, the erythro- and threo-amino alcohols of bupropion, the erythro-amino diol of bupropion and hydroxybupropion), lobeline, selegiline, risperidone and its 9-hydroxy metabolite, desmethylselegiline, substituted pyridine derivatives (*e.g.*, 1-[(6-chloro-3-pyridinyl)methyl]-2-imidazolidine, 1-[(6-chloro-3-pyridinyl)methyl]-2-imidazothiazole and analogs thereof), methcamylamine, desipramine, fluoxetine, ropinirole, trimethaphan, trimethaphan camsylate, doxepin, 2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, anxiolytics (*e.g.*, isovaleramide), γ -vinyl GABA (GVG), epibatidine and derivatives thereof, 7-azabicyclo-[2.2.1]-heptane and -heptene compounds, naltrexone, nalmefene, ketamine, hexamethonium, pentolinium, dihydro- β -erythroidine, erysodine, d-tubocurarine, pempidine, chlorisondamine, amantadine, hetero-oxy alkanamines, benzyldiene- and cinnamylidene-anabasines, azaindole-ethylamine derivatives, N-(pyridinylmethyl)-heterocyclylideneamines and NK-1 receptor antagonists (*e.g.*, 9-bromo-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one).

In another embodiment a drug contained in the core of the tablet is an antibacterial drug. Illustratively such a drug can be an antibiotic, for example an aminoglycoside, amphenicol, ansamycin, carbapenem, cephalosporin, cephamycin, monobactam, oxacephem, penicillin, lincosamide, macrolide, polypeptide or tetracycline; or a synthetic antibacterial, for example a 2,4-diaminopyrimidine, nitrofurantoin, oxazolidinone, quinolone or analog thereof, sulfonamide or sulfone. Presently preferred antibacterials include the following illustrative examples: amikacin, azithromycin, cefixime, cefoperazone, cefotaxime, ceftazidime, ceftizoxime, ceftriaxone, chloramphenicol, ciprofloxacin, clindamycin, colistin, domeclocycline, doxycycline, erythromycin, gentamicin, lincomycin, linezolid, mafenide, methacycline, minocycline, neomycin, norfloxacin, ofloxacin, oxytetracycline, pirlimycin, polymyxin B, pyrimethamine, silver sulfadiazine, sulfacetamide, sulfisoxazole, tetracycline, tobramycin, trimethoprim and combinations thereof. In one embodiment an antibacterial drug present in the core of the tablet is an oxazolidinone, for example selected from (S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide (eperezolid), (S)-N-[[3-[3-fluoro-4-[4-(morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide (linezolid), N-[(5S)-3-[3-fluoro-4-[4-(2-fluoroethyl)-3-oxo-1-piperazinyl]phenyl]-2-oxo-5-

oxazolidinyl)methyl]acetamide, (S)-N-[[3-[5-(3-pyridyl)thiophen-2-yl]-2-oxo-5-oxazolidinyl)methyl]acetamide, and (S)-N-[[3-[5-(4-pyridyl)pyrid-2-yl]-2-oxo-5-oxazolidinyl)methyl]acetamide hydrochloride.

In another embodiment a drug contained in the core of the tablet is an
5 antimigraine agent. Illustratively such an agent is an alkylxanthine, for example caffeine; a dopamine D₂ receptor agonist, for example alpiropride or lisuride; a GABA_A receptor modulator, for example ganaxolone; a 5-hydroxytryptamine (5-HT) receptor agonist, for example almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan or zolmitriptan; ergot or a derivative thereof, for example
10 ergotamine or dihydroergotamine; or a vasomodulator, for example dotarizine, fonazine or lomerizine.

In another embodiment a drug contained in the core of the tablet is useful in treating or preventing an ophthalmic disorder.

Illustratively such an ophthalmic drug can be an antibacterial, for example
15 selected from the classes listed above.

Alternatively or in addition, such an ophthalmic drug can illustratively be an antiglaucoma or intraocular pressure lowering agent, such as (a) an α -adrenergic agonist or sympathomimetic, *e.g.*, adrenolone, apraclonidine, brimonidine or dipivefrin; (b) a β -adrenergic blocker, *e.g.*, acebutolol, adaprolol, alprenolol, atenolol, betaxolol, bufetolol, bufuralol, bunitrolol, bunolol, bupranolol, carteolol, carvedilol, cetamolol,
20 dexpropanolol, labetalol, levobunolol, metipranolol, metoprolol, nadolol, nifenalol, oxyprenolol, penbutolol, pindolol, practolol, pronethalol, propranolol, sotalol, timolol, tolamolol, toliprolol or vaninolol; (c) a carbonic anhydrase inhibitor, *e.g.*, acetazolamide or dorzolamide; or (d) a prostaglandin or analog thereof, *e.g.*, PGF_{2 α} analogs such as bimatoprost, latanoprost, travoprost and unoprostone isopropyl
25

Alternatively or in addition, such an ophthalmic drug can illustratively be a miotic, *e.g.*, carbachol, physostigmine or pilocarpine.


Alternatively or in addition, such an ophthalmic drug can illustratively be an anti-inflammatory agent, for example an NSAID, more preferably a selective COX-2
30 inhibitory drug, for example selected from those listed below.

In another embodiment a drug contained in the core of the tablet is an analgesic, antipyretic or anti-inflammatory agent, *e.g.*, aceclofenac, acemetacin,

e-acetamidocaproic acid, acetaminophen, acetaminosalol, acetanilide, acetylsalicylic acid (aspirin), *S*-adenosylmethionine, alclofenac, alclometasone, alfentanil, algestone, allylprodine, alminoprofen, aloxiprin, alphaprodine, aluminum bis(acetylsalicylate), amcinonide, amfenac, aminochlorthenoxazin, 3-amino-4-hydroxybutyric acid, 2-amino-
5 4-picoline, aminopropylon, aminopyrine, amixetrine, ammonium salicylate, ampiroxicam, amtolmetin guacil, anileridine, antipyrine, antrafenine, apazone, beclomethasone, bendazac, benorylate, benoxaprofen, benzpiperylon, benzydamine, benzylmorphine, bermoprofen, betamethasone, bezitramide, α -bisabolol, bromfenac, *p*-bromoacetanilide, 5-bromosalicylic acid acetate, bromosaligenin, bucetin, bucloxic
10 acid, bucolome, budesonide, bufexamac, bumadizon, buprenorphine, butacetin, butibufen, butophanol, carbamazepine, carbiphen, carprofen, carsalam, celecoxib, chlorobutanol, chloroprednisone, chlorthenoxazin, choline salicylate, cinchophen, cinmetacin, ciramadol, clidanac, clobetasol, clocortolone, clometacin, clonitazene, clonixin, clopirac, cloprednol, clove, codeine, codeine methyl bromide, codeine
15 phosphate, codeine sulfate, cortisone, cortivazol, cropropamide, crotethamide, deflazacort, desomorphine, desonide, desoximetasone, dexamethasone, dexoxadrol, dextromoramide, dezocine, diampromide, diclofenac, difenamizole, difenpiramide, diflorasone, diflucortolone, diflumisal, difluprednate, dihydrocodeine, dihydrocodeinone enol acetate, dihydromorphine, dihydroxyaluminum acetylsalicylate, dimenoxadol,
20 dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, diprocetyl, dipyrone, ditazol, droxicam, emorfazone, enfenamic acid, enoxolone, epirizole, eptazocine, etersalate, ethenzamide, ethoheptazine, ethoxazene, ethylmethylthiambutene, ethylmorphine, etodolac, etofenamate, etonitazene, etoricoxib, eugenol, felbinac, fenbufen, fenclozic acid, fendosal, fenoprofen, fentanyl,
25 fentiazac, fepradinol, feprazone, floctafenine, fluazacort, flucloronide, flufenamic acid, flumethasone, flunisolide, flunixin, flunoxaprofen, fluocinolone acetonide, fluocimionide, fluocortin butyl, fluocortolone, fluoresone, fluorometholone, fluperolone, flupirtine, fluprednidene, fluprednisolone, fluproquazone, flurandrenolide, flurbiprofen, formocortal, fosfosal, gentisic acid, glafenine, glucametacin, glycol salicylate,
30 guaiazulene, halcinonide, halometasone, haloprednone, hydrocodone, hydrocortamate, hydrocortisone, hydromorphone, hydroxypethidine, ibufenac, ibuprofen, ibuproxam, imidazole salicylate, indomethacin, indoprofen, isofezolac, isoladol, isomethadone,

- isonixin, isoxepac, isoxicam, ketobemidone, ketoprofen, ketorolac, *p*-lactophenetide, lefetamine, levorphanol, lofentanil, lonazolac, lornoxicam, loxoprofen, lysine acetylsalicylate, mazipredone, meclofenamic acid, medrysone, mefenamic acid, meperidine, meprednisone, meptazinol, mesalamine, metazocine, methadone, 5 methotrimeprazine, methylprednisolone, metiazinic acid, metofoline, metopon, mofebutazone, mofezolac, morazone, morphine, morphine hydrochloride, morphine sulfate, morpholine salicylate, myrophine, nabumetone, nalbuphine, 1-naphthyl salicylate, naproxen, narceine, nefopam, nicomorphine, nifenazone, niflumic acid, nimesulide, 5'-nitro-2'-propoxyacetanilide, norlevorphanol, normethadone, 10 normorphine, norpipanone, olsalazine, opium, oxaceprol, oxametacine, oxaprozin, oxycodone, oxymorphone, oxyphenbutazone, papaveretum, paramethasone, paranyline, parecoxib, parsalmide, pentazocine, perisoxal, phenacetin, phenadoxone, phenazocine, phenazopyridine hydrochloride, phenocoll, phenoperidine, phenopyrazone, phenyl acetylsalicylate, phenylbutazone, phenyl salicylate, 15 phenylramidol, piketoprofen, piminodine, pipebuzone, piperylone, pirofen, pirazolac, piritramide, piroxicam, pranoprofen, prednicarbate, prednisolone, prednisone, prednival, prednylidene, proglumetacin, proheptazine, promedol, propacetamol, propiram, propoxyphene, propyphenazone, proquazone, protizinic acid, proxazole, ramifenazone, remifentanil, rimazolium metilsulfate, rofecoxib, salacetamide, salicin, 20 salicylamide, salicylamide *o*-acetic acid, salicylic acid, salicylsulfuric acid, salsalate, salverine, simetride, sufentanil, sulfasalazine, sulindac, superoxide dismutase, suprofen, suxibuzone, talniflumate, tenidap, tenoxicam, terofenamate, tetrandrine, thiazolinobutazone, tiaprofenic acid, tiaramide, tilidine, tinoridine, tixocortol, tolfenamic acid, tolmetin, tramadol, triamcinolone, tropesin, valdecoxib, viminol, 25 xenbucin, ximoprofen, zaltoprofen or zomepirac.

In a particular embodiment such a drug is a selective COX-2 inhibitory drug, for example a compound of formula (I):




or a prodrug thereof or a pharmaceutically acceptable salt thereof, wherein:

- A is a substituent selected from partially unsaturated or unsaturated heterocyclyl and partially unsaturated or unsaturated carbocyclic rings, preferably a heterocyclyl group selected from pyrazolyl, furanonyl, isoxazolyl, pyridinyl, cyclopentenonyl and pyridazinonyl groups;
- X is O, S or CH₂;
- n is 0 or 1;
- R¹¹ is at least one substituent selected from heterocyclyl, cycloalkyl, cycloalkenyl and aryl, and is optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy and alkylthio;
- R¹² is methyl, amino or aminocarbonylalkyl;
- R¹³ is one or more radicals selected from hydrido, halo, alkyl, alkenyl, alkynyl, oxo, cyano, carboxyl, cyanoalkyl, heterocycloxy, alkyloxy, alkylthio, alkylcarbonyl, cycloalkyl, aryl, haloalkyl, heterocyclyl, cycloalkenyl, aralkyl, heterocyclylalkyl, acyl, alkylthioalkyl, hydroxyalkyl, alkoxycarbonyl, arylcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl, aralkoxyalkyl, alkoxyaralkoxyalkyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl, N-arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, alkylaminocarbonylalkyl, carboxyalkyl, alkylamino, N-aryl-amino, N-aralkylamino, N-alkyl-N-aralkylamino, N-alkyl-N-aryl-amino, aminoalkyl, alkylaminoalkyl, N-arylaminalkyl, N-aralkylaminalkyl, N-alkyl-N-aralkylaminalkyl, N-alkyl-N-


arylaminoalkyl, aryloxy, aralkoxy, arylthio, aralkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, N-arylaminosulfonyl, arylsulfonyl and N-alkyl-N-arylaminosulfonyl, R^{13} being optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy and alkylthio; and R^{14} is selected from hydrido and halo.

In a preferred composition according to the present embodiment the selective COX-2 inhibitory drug is a compound having the formula (II):



where R^{15} is a methyl, amino or imide group, R^{16} is hydrogen or a C_{1-4} alkyl or alkoxy group, X is N or CR^{17} where R^{17} is hydrogen or halogen, and Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a five- to six-membered ring that is unsubstituted or substituted at one or more positions with oxo, halo, methyl or halomethyl groups. Preferred such five- to six-membered rings are cyclopentenone, furanone, methylpyrazole, isoxazole and pyridine rings substituted at no more than one position.

In another preferred composition according to the present embodiment the selective COX-2 inhibitory drug is a compound having the formula (III):



or a prodrug thereof or a pharmaceutically acceptable salt thereof, where X'' is O, S or N-lower alkyl; R^{18} is lower haloalkyl; R^{19} is hydrogen or halogen; R^{20} is hydrogen,

halogen, lower alkyl, lower alkoxy or haloalkoxy, lower aralkylcarbonyl, lower dialkylaminosulfonyl, lower alkylaminosulfonyl, lower aralkylaminosulfonyl, lower heteroaralkylaminosulfonyl, or 5- or 6- membered nitrogen-containing heterocyclosulfonyl; and R²¹ and R²² are independently hydrogen, halogen, lower alkyl, lower alkoxy, or aryl.

A particularly useful compound of formula (III) is (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid.

In yet another preferred composition according to the present embodiment the selective COX-2 inhibitory drug is a 5-alkyl-2-arylaminophenylacetic acid or derivative thereof. Particularly useful compounds of this class are 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid and pharmaceutically acceptable salts thereof.


Illustratively, celecoxib, deracoxib, valdecoxib, parecoxib, rofecoxib, etoricoxib, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one, (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid, 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methyl-1-butyloxy)-5-[4-(methylsulfonyl)phenyl]-3-(2H)-pyridazinone and salts thereof are useful in compositions of the invention:

For example, the selective COX-2 inhibitory drug or prodrug thereof can be selected from celecoxib, valdecoxib, parecoxib, rofecoxib, etoricoxib, (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid and salts thereof.

In another embodiment, a drug contained in the core of the tablet is useful in treatment and/or prevention of sexual dysfunction in male and/or female subjects. Such a drug can illustratively be (a) a phosphodiesterase type 5 (PDE5) inhibitor, *e.g.*, sildenafil, tadalafil or vardenafil, (b) a cyclic GMP phosphodiesterase inhibitor, (c) a cyclic AMP activator, (d) an α -adrenergic antagonist, *e.g.*, phentolamine or yohimbine, or (e) a dopaminergic agonist, *e.g.*, apomorphine. Such a drug can be a compound of formula (V) below. Alternatively, a drug contained in the core of the tablet can be other than a drug useful in treatment and/or prevention of sexual dysfunction. As another alternative, a drug contained in the core of the tablet can be useful in treatment and/or prevention of sexual dysfunction but is other than a compound of formula (V) below.

In illustrative compositions a drug useful for example in treatment of Parkinson's disease or sexual dysfunction is present in the core of the tablet and is a

compound of formula (V)



or a pharmaceutically acceptable salt thereof, wherein

5 R^1 , R^2 and R^3 are the same or different and are H, C_{1-6} alkyl (optionally phenyl substituted), C_{3-5} alkenyl or alkynyl or C_{3-10} cycloalkyl, or where R^3 is as above and R^1 and R^2 are cyclized with the attached N atom to form pyrrolidinyl, piperidinyl, morpholinyl, 4-methylpiperazinyl or imidazolyl groups;

10 X is H, F, Cl, Br, I, OH, C_{1-6} alkyl or alkoxy, CN, carboxamide, carboxyl or (C_{1-6} alkyl)carbonyl;

A is CH, CH_2 , CHF, CHCl, CHBr, CHI, $CHCH_3$, C=O, C=S, CSCH₃, C=NH, CNH₂, CNHCH₃, CNHCOOCH₃, CNHCN, SO₂ or N;

B is CH, CH_2 , CHF, CHCl, CHBr, CHI, C=O, N, NH or NCH₃, and n is 0 or 1; and

15 D is CH, CH_2 , CHF, CHCl, CHBr, CHI, C=O, O, N, NH or NCH₃.

It is preferred that the compound of formula (V) or salt thereof is water-soluble.


Pharmaceutically acceptable salts of a compound of formula (V) include without restriction salts of the following acids: hydrochloric, hydrobromic, sulfuric, methanesulfonic, phosphoric, nitric, benzoic, citric, tartaric, fumaric and maleic acids, 20 and mono- and dicarboxylic acids of formula $CH_3-(CH_2)_n-COOH$ and $HOOC-(CH_2)_n-COOH$ where n is 0 to 4, for example malonic acid.

Particularly preferred salts are the hydrochloride salt and the maleate, *i.e.*, (Z)-2-butenedioate, salt.

Compounds of formula (V) and their salts can be prepared by processes known 25 *per se*, including processes described in patent literature cited herein. However, the present invention is not restricted by the process used to prepare the therapeutic agent.

Preferred compounds of formula (V) are those disclosed generically or

specifically in U.S. Patent No. 5,273,975 to Moon *et al.* Especially preferred compounds are those of formula (VI)



wherein X is O or S, and pharmaceutically acceptable salts thereof.

5 Tablet cores useful according to the invention can be prepared by any suitable process known in the art. A core according to the invention comprises a matrix wherein are distributed solid particles of a water-soluble dye. Any suitable excipient or excipients can form the matrix. For peroral tablets the matrix typically comprises a diluent or carrier, for example lactose and/or starch, and can further comprise
10 additional excipients such as binders, disintegrants, wetting agents, *etc.* For intraoral tablets the matrix typically comprises a water-soluble sugar, for example mannitol and/or maltose. If a drug is present in the core, the drug, too, is distributed in the matrix.

 The ultimate appearance of the tablet depends in part upon the selection of
15 water-soluble dye and the number and size of the solid particles of the dye. For example, relatively large particles will tend to produce a speckled pattern having larger blocks of color than will be produced by smaller particles; and a relatively large number of particles will tend to produce a speckled pattern where the color covers a greater portion of the tablet surface than will be produced by fewer particles. A more
20 water-soluble dye will tend to produce larger and/or less discrete blocks of color than will be produced by a less water-soluble dye.

 Optionally solid particles of more than one water-soluble dye can be present in the core, contributing a bicolored or multicolored speckled appearance to the tablet.

 The core is coated with a coating composition comprising gellan gum, as more
25 fully described below. The coating is typically present in an amount representing a weight gain of about 0.1% to about 5%, but greater or lesser amounts can be used if desired. Preferably the gellan gum constitutes about 25% to 100%, more preferably about 50% to 100%, by weight of the coating.

Preferably the coating is an excipient coating. An "excipient coating" herein is a coating consisting, at least at the time of application of the coating to the core, only of excipient materials, *i.e.*, having substantially no drug present therein. It will be understood that during manufacture and storage some migration of a drug substance
5 can potentially occur from the core to the coating of a tablet of the invention, but this is generally minimal. Thus a drug substance, if present in the tablet, is largely confined to the core where it is not commingled with gellan gum.

Any gellan gum can be used in the coating composition, but it is preferred to use a deacylated gellan gum such as that sold under the trademark Kelcogel™.
10 Optionally one or more additional gums and/or biopolymers, for example alginates, can be present in the coating composition.

The coating composition comprises a sprayable vehicle, preferably water, having dissolved or dispersed therein a gellan gum and optionally one or more additional excipients. Preferably the coating composition has a total solids
15 concentration of about 1% to about 10% by weight, and a gellan gum concentration of about 1% to about 5% by weight.

Additional excipients present in the coating composition can include one or more buffering agents, typically at a concentration of about 0.03% to about 3% by weight; one or more plasticizers, typically at a concentration of about 0.03% to about
20 3% by weight; and/or one or more dispersing and/or emulsifying agents, typically at a concentration of about 0.03% to about 3% by weight. An example of a suitable buffering agent is sodium citrate. An example of a suitable plasticizer is propylene glycol. An example of a suitable dispersing or emulsifying agent is lecithin. Flavoring agents can also be included in the coating composition if desired.

25 The coating composition can be prepared by any suitable process involving dissolving the gellan gum and other, optional, excipients in the vehicle, preferably water. Order of addition is not critical. The water is preferably heated, for example to a temperature of about 55°C to about 85°C. Gellan gum and other excipients, if present, are added with stirring until all ingredients are homogeneously dispersed. The
30 resulting coating liquid is preferably maintained at an elevated temperature during the stirring and subsequent spraying procedure.

Tablet cores to be coated are placed in a suitable coating apparatus, for

example a coating pan, and are preferably preheated to a bed temperature of about 50°C to about 70°C. The coating liquid is sprayed on to the tablets under conditions that will be readily optimized by one of skill in the art. Spraying is continued until an amount of coating solution equivalent to a weight gain of about 0.1% to about 5% has
 5 been applied. The resulting coated tablets are preferably cooled to ambient temperature, or about 20°C to about 35°C, prior to discharge from the coating pan.

Coating and cooling conditions can also affect the precise color pattern of the finished tablet. For example, if coating is done at lower temperatures and/or if cooling occurs slowly, so that the solid dye particles in the core are exposed to water for a
 10 longer period of time, a speckled pattern with larger blocks of color will typically result.

An illustrative sublingual tablet of the invention containing as active agent a salt, *e.g.*, the maleate salt, of sumanirole or (*R*)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-*ij*]-quinoline-2(1H)-thione has a core having the following composition:

15	active agent	0.1–3% free base equivalent
	mannitol	50–90%
	powdered sorbitol	10–40%
	hydroxypropylcellulose	0–10%
	xanthan gum	0–5%
20	flavoring agent	0–0.5%
	water-soluble dye	0–0.5%
	colloidal silicon dioxide	0–1%
	magnesium stearate	0.5–5%

all percentages being by weight.

25 Another illustrative sublingual tablet of the invention containing as active agent a salt, *e.g.*, the maleate salt, of sumanirole or (*R*)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-*ij*]-quinoline-2(1H)-thione has a core having the following composition:

	active agent	0.1–3% free base equivalent
	lactose monohydrate	50–85%
30	pregelatinized starch	10–45%
	xanthan gum	0–5%
	flavoring agent	0–0.5%

water-soluble dye	0–0.5%
colloidal silicon dioxide	0–1%
magnesium stearate	0.5–5%

all percentages being by weight.

- 5 Yet another illustrative sublingual tablet of the invention containing as active agent a salt, *e.g.*, the maleate salt, of sumanirole or (*R*)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-*ij*]-quinoline-2(1H)-thione has a core having the following composition:

	active agent	0.1–3% free base equivalent
10	microcrystalline cellulose	30–70%
	pregelatinized starch	25–65%
	croscarmellose sodium	0–10%
	xanthan gum	0–5%
	flavoring agent	0–0.5%
15	water-soluble dye	0–0.5%
	colloidal silicon dioxide	0–1%
	magnesium stearate	0.5–5%

all percentages being by weight.

EXAMPLES

- 20 The following examples illustrate aspects of the present invention but should not be construed as limitations. In these examples “compound Z” refers to (*R*)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-*ij*]-quinoline-2(1H)-thione, maleate salt. All percentages are by weight unless otherwise indicated.

Example 1

- 25 A sublingual tablet formulation was prepared having the following composition:

	compound Z	1.11%
	Avicel™ PH-101 (microcrystalline cellulose)	46.71%
	Starch 1500 of Colorcon (pregelatinized starch)	44.00%
30	croscarmellose sodium NF	5.00%
	colloidal silicon dioxide NF	0.50%

cinnamon flavor	0.14%
mint flavor	0.04%
dye (cherry shade #1632, Crompton & Knowles)	0.50%
magnesium stearate	2.00%

5 Pregelatinized starch and dye were blended in a high-shear mixer for 2 minutes or until homogeneously mixed. The following ingredients were then individually layered over the resulting mixture in the high-shear mixer: compound Z; microcrystalline cellulose; colloidal silicon dioxide; croscarmellose sodium. Mixing in the high-shear mixer was resumed for a further 2 minutes. If the dye was not

10 adequately dispersed throughout the resulting mixture, mixing continued in 1 minute increments until good dispersion of dye was observed. A small portion of the mixture was then removed and hand-mixed with magnesium stearate to form a magnesium stearate premix. This premix, together with the flavors, was added to the high-shear mixer and mixed for 1 minute to form a lubricated tablet stock.

15 The lubricated tablet stock was discharged from the high-shear mixer and stored in desiccated hermetically sealed containers until ready for tableting. Tablets were prepared by compression using 12/32 inch (approximately 9 mm) Plain/Plain tooling with slight curvature to the following specifications:

20 tablet weight	180 mg
hardness	3-4 SCU
friability	<0.5%

Example 2

Sublingual tablets prepared as in Example 1 were coated with a gellan gum coating according to the following procedure.

25 A coating liquid having the following composition was prepared:

gellan gum (Kelcogel™)	2.00%
sodium citrate	0.13%
propylene glycol	0.40%
lecithin	0.20%
30 deionized water	97.27%

Deionized water was heated to 70°C. The other ingredients were added with stirring until all ingredients were homogeneously dispersed. The resulting coating

liquid having a solids content of 2.73% was maintained at a temperature of 70°C during the stirring and subsequent spraying procedure.

Tablets of Example 1, in an amount of 700 g, were placed in a 12 inch (approximately 300 mm) coating pan and preheated to a bed temperature of 60°C.

5 The coating liquid was sprayed on to the tablets under the following conditions:

	outlet air temperature	50–60°C
	pan speed	16 rpm
	air flow	30–35 cfm (0.84–0.98 m ³ /minute)
	atomizing air pressure	10 psi (69 kPa)
10	peristaltic pump setting	15–20 g/minute

Spraying was continued until an amount of coating solution equivalent to a weight gain of 1.2% had been applied. The resulting coated tablets were cooled to 30°C prior to discharge from the coating pan.

The tablets had an attractive high gloss appearance with cherry red speckles.

15 Example 3

A sublingual tablet formulation was prepared having the following composition:

	compound Z	1.05%
	mannitol, granular	70.00%
20	sorbitol	16.57%
	hydroxypropylcellulose, type LH-11	7.00%
	xanthan gum	2.50%
	colloidal silicon dioxide NF	0.50%
	cinnamon flavor	0.14%
25	mint flavor	0.04%
	dye (cherry shade #1632, Crompton & Knowles)	0.20%
	magnesium stearate	2.00%

Mannitol and dye were blended in a high-shear mixer for 2 minutes or until homogeneously mixed. The following ingredients were then individually layered over
 30 the resulting mixture in the high-shear mixer: compound Z; sorbitol; hydroxypropylcellulose; xanthan gum; colloidal silicon dioxide. Mixing in the high-shear mixer was resumed for a further 2 minutes. If the dye was not adequately

dispersed throughout the resulting mixture, mixing continued in 1 minute increments until good dispersion of dye was observed. A small portion of the mixture was then removed and hand-mixed with magnesium stearate to form a magnesium stearate premix. This premix, together with the flavors, was added to the high-shear mixer and
 5 mixed for 1 minute to form a lubricated tablet stock.

The lubricated tablet stock was discharged from the high-shear mixer and stored in desiccated hermetically sealed containers until ready for tableting. Tablets were prepared by compression using 12/32 inch (approximately 9 mm) Plain/Plain tooling with slight curvature to the following specifications:

10	tablet weight	190 mg
	hardness	3-4 SCU
	friability	<0.5%

Example 4

Sublingual tablets prepared as in Example 3 were coated with a gellan gum
 15 coating according to the following procedure.

A coating liquid having the following composition was prepared:

	gellan gum (Kelcogel™)	2.00%
	sodium citrate	0.13%
	propylene glycol	0.40%
20	lecithin (Lipoid™ LS-100)	0.20%
	flavor	0.30%
	deionized water	96.97%

Deionized water was heated to 70°C. The other ingredients were added with stirring until all ingredients were homogeneously dispersed. The resulting coating
 25 liquid having a solids content of 3.03% was maintained at a temperature of 70°C during the stirring and subsequent spraying procedure.

Tablets of Example 1, in an amount of 700 g, were placed in a 12 inch (approximately 300 mm) coating pan and preheated to a bed temperature of 60°C. The coating liquid was sprayed on to the tablets under the following conditions:

30	outlet air temperature	50–60°C
	pan speed	16 rpm
	air flow	30–35 cfm (0.84–0.98 m ³ /minute)

atomizing air pressure	10 psi (69 kPa)
peristaltic pump setting	15-20 g/minute

Spraying was continued until an amount of coating solution equivalent to a weight gain of 1.36% had been applied. The resulting coated tablets were cooled to
 5 30°C prior to discharge from the coating pan.

The tablets had an attractive high gloss appearance with cherry red speckles.

Example 5

A sublingual tablet formulation was prepared having the following composition:

10	compound Z	0.43%
	Avicel™ PH-101 (microcrystalline cellulose)	47.39%
	Starch 1500 of Colorcon (pregelatinized starch)	44.00%
	croscarmellose sodium NF	5.00%
	colloidal silicon dioxide NF	0.50%
15	cinnamon flavor	0.14%
	mint flavor	0.04%
	color (cherry shade #1632, Crompton & Knowles)	0.50%
	magnesium stearate	2.00%

Pregelatinized starch and color were blended in a high-shear mixer for 2
 20 minutes or until homogeneously mixed. The following ingredients were then individually layered over the resulting mixture in the high-shear mixer: compound Z; microcrystalline cellulose; colloidal silicon dioxide; croscarmellose sodium. Mixing in the high-shear mixer was resumed for a further 2 minutes. If the color was not adequately dispersed throughout the resulting mixture, mixing continued in 1 minute
 25 increments until good dispersion of color was observed. A small portion of the mixture was then removed and hand-mixed with magnesium stearate to form a magnesium stearate premix. This premix, together with the flavors, was hand screened through a #20 mesh pharmaceutical screen, then added to the high-shear mixer and mixed for 1 minute to form a lubricated tablet stock.

30 The lubricated tablet stock was discharged from the high-shear mixer and stored in desiccated hermetically sealed containers until ready for tableting. Tablets were prepared by compression using 12/32 inch (approximately 9 mm) Plain/Plain

tooling with slight curvature to the following specifications:

tablet weight	180 mg
hardness	3.5–4 SCU
friability	<0.8%

5 Example 6

Sublingual tablets prepared as in Example 5 were coated with a gellan gum coating according to the following procedure.

A coating liquid having the following composition was prepared:

	gellan gum (Kelcogel™)	2.00%
10	sodium citrate	0.13%
	propylene glycol	0.40%
	lecithin (Lipoid™ LS-100)	0.20%
	hot cinnamon flavor	0.30%
	deionized water	96.97%

15 Deionized water was heated to 70°C. The other ingredients were added with stirring until all ingredients were homogeneously dispersed. The resulting coating liquid having a solids content of 3.03% was maintained at a temperature of 70°C during the stirring and subsequent spraying procedure.

20 Tablets of Example 5, in an amount of 7000 g, were placed in a 24 inch (approximately 600 mm) coating pan and preheated to a bed temperature of 60°C. The coating liquid was sprayed on to the tablets under the following conditions:

	outlet air temperature	48–55°C
	pan speed	10–14 rpm, preferably 14 rpm
	air flow	300–400 cfm (8.5–11.3 m ³ /minute)
25	atomizing air pressure	20–35 psi (138–242 kPa), preferably about 20 psi
	peristaltic pump setting	15–40 g/minute/gun (2 gun spray system), preferably 30–40 g/minute/gun
	tablet bed temp	37–50°C, preferably about 40°C

30 Spraying was continued until an amount of coating solution equivalent to a weight gain of 2.04% had been applied. The resulting coated tablets were cooled to 30°C prior to discharge from the coating pan.

The tablets had an attractive high gloss appearance with cherry red speckles.

WHAT IS CLAIMED IS:

1. A pharmaceutical tablet comprising a core and a coating adherent thereto, wherein (a) the core comprises solid particles of a water-soluble dye distributed in a matrix, and (b) the coating comprises gellan gum.
- 5 2. The tablet of Claim 1 having a speckled surface appearance.
3. The tablet of Claim 1 wherein the core comprises a drug in a therapeutically and/or prophylactically effective amount.
4. The tablet of Claim 3 wherein the drug is selected from the group consisting of
10 ACE inhibitors; α -adrenergic agonists; β -adrenergic agonists; α -adrenergic blockers; β -adrenergic blockers; alcohol deterrents; aldose reductase inhibitors; aldosterone antagonists; amino acids; anabolics; analgesics (both narcotic and non-narcotic); anesthetics; anorexics; antacids; anthelmintics; antiacne agents; antiallergics; antiandrogens; antianginal agents; antianxiety agents; antiarrhythmics; antiasthmatics; antibacterial agents and antibiotics; antialopecia
15 and antibaldness agents; antiamebics; antibodies; anticholinergic drugs; anticoagulants and blood thinners; anticolitis drugs; anticonvulsants; anticystitis drugs; antidepressants; antidiabetic agents; antidiarrheals; antidiuretics; antidotes; antiemetics; antiestrogens; antifatulents; antifungal agents; antigens; antiglaucoma agents; antihistaminics; antihyperactives;
20 antihyperlipoproteinemics; antihypertensives; antihyperthyroid agents; antihypotensives; antihypothyroid agents; anti-infectives; anti-inflammatories (both steroidal and nonsteroidal); antimalarial agents; antimigraine agents; antineoplastics; antiobesity agents; antiparkinsonian agents and antidyskinetics; antipneumonia agents; antiprotozoal agents; antipruritics; antipsoriatics;
25 antipsychotics; antipyretics; antirheumatics; antisecretory agents; anti-shock medications; antispasmodics; antithrombotics; antitumor agents; antitussives; antiulceratives; antiviral agents; anxiolytics; bactericidins; bone densifiers; bronchodilators; calcium channel blockers; carbonic anhydrase inhibitors; cardiotonics and heart stimulants; chemotherapeutics; choleretics; cholinergics;
30 chronic fatigue syndrome medications; CNS stimulants; coagulants; contraceptives; cystic fibrosis medications; decongestants; diuretics; dopamine

- receptor agonists; dopamine receptor antagonists; enzymes; estrogens; expectorants; gastric hyperactivity medications; glucocorticoids; hemostatics; HMG CoA reductase inhibitors; hormones; hypnotics; immunomodulators; immunosuppressants; laxatives; medicaments for oral and periodontal diseases; 5 miotics; monoamine oxidase inhibitors; mucolytics; multiple sclerosis medications; muscle relaxants; mydriatics; narcotic antagonists; NMDA receptor antagonists; oligonucleotides; ophthalmic drugs; oxytocics; peptides, polypeptides and proteins; polysaccharides; progestogens; prostaglandins; protease inhibitors; respiratory stimulants; sedatives; serotonin uptake inhibitors; 10 sex hormones including androgens; smoking cessation drugs; smooth muscle relaxants; smooth muscle stimulants; thrombolytics; tranquilizers; urinary acidifiers; urinary incontinence medications; vasodilators; vasoprotectants; and combinations thereof.
5. The tablet of Claim 3 wherein the drug is a smoking cessation drug.
 - 15 6. The tablet of Claim 5 wherein the smoking cessation drug is selected from bupropion, ibogaine, nicotine and metabolites thereof.
 7. The tablet of Claim 3 wherein the drug is an antibacterial drug.
 8. The tablet of Claim 7 wherein the antibacterial drug is an oxazolidinone.
 9. The tablet of Claim 8 wherein the oxazolidinone is selected from eperezolid, 20 linezolid, N-[(5*S*)-3-[3-fluoro-4-[4-(2-fluoroethyl)-3-oxo-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, (*S*)-N-[[3-[5-(3-pyridyl)thiophen-2-yl]-2-oxo-5-oxazolidinyl]methyl]acetamide, and (*S*)-N-[[3-[5-(4-pyridyl)pyrid-2-yl]-2-oxo-5-oxazolidinyl]methyl]acetamide hydrochloride.
 10. The tablet of Claim 3 wherein the drug is an antimigraine agent.
 - 25 11. The tablet of Claim 10 wherein the antimigraine agent is a 5-HT receptor agonist.
 12. The tablet of Claim 11 wherein the 5-HT receptor agonist is selected from the group consisting of almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan or zolmitriptan.
 13. The tablet of Claim 3 wherein the drug is useful in treating or preventing an


ophthalmic disorder.

14. The tablet of Claim 13 wherein the drug is an antiglaucoma or intraocular pressure lowering agent.
15. The tablet of Claim 14 wherein the antiglaucoma or intraocular pressure lowering agent is selected from the group consisting of adrenolone, apraclonidine, 5
brimonidine, dipivefrin, acebutolol, adaprolol, alprenolol, atenolol, betaxolol, bufetolol, bufuralol, bunitrolol, bunolol, bupranolol, carteolol, carvedilol, cetamolol, dexpropanolol, labetalol, levobunolol, metipranolol, metoprolol, nadolol, nifenalol, oxyprenolol, penbutolol, pindolol, practolol, pronethalol, 10
propranolol, sotalol, timolol, tolamolol, toliprolol, vaninolol, acetazolamide, dorzolamide, bimatoprost, latanoprost, travoprost, unoprostone isopropyl and combinations thereof.
16. The tablet of Claim 3 wherein the drug is an analgesic, antipyretic or anti-inflammatory agent.
- 15 17. The tablet of Claim 16 wherein the analgesic, antipyretic or anti-inflammatory agent is selected from the group consisting of aceclofenac, acemetacin, *e*-acetamidocaproic acid, acetaminophen, acetaminosalol, acetanilide, acetylsalicylic acid, *S*-adenosylmethionine, alclofenac, alclometasone, alfentanil, algestone, allylprodine, alminoprofen, aloxiprin, alphaprodine, aluminum 20
bis(acetylsalicylate), amcinonide, amfenac, aminochlorthenoxazin, 3-amino-4-hydroxybutyric acid, 2-amino-4-picoline, aminopropylon, aminopyrine, amixetrine, ammonium salicylate, ampiroxicam, amtolmetin guacil, anileridine, antipyrine, antrafenine, apazone, beclomethasone, bendazac, benorylate, benoxaprofen, benzpiperylon, benzydamine, benzylmorphine, bermoprofen, 25
betamethasone, bezitramide, α -bisabolol, bromfenac, *p*-bromoacetanilide, 5-bromosalicylic acid acetate, bromosaligenin, bucetin, bucloxic acid, bucolome, budesonide, bufexamac, bumadizon, buprenorphine, butacetin, butibufen, butophanol, carbamazepine, carbiphene, carprofen, carsalam, celecoxib, chlorobutanol, chloroprednisone, chlorthenoxazin, choline salicylate, cinchophen, 30
cinmetacin, ciramadol, clidanac, clobetasol, clocortolone, clometacin, clonitazene, clonixin, clopirac, cloprednol, clove, codeine, codeine methyl

bromide, codeine phosphate, codeine sulfate, cortisone, cortivazol,
 cropropamide, crotethamide, deflazacort, desomorphine, desonide,
 desoximetasone, dexamethasone, dexoxadrol, dextromoramide, dezocine,
 diampromide, diclofenac, difenamizole, difenpiramide, diflorasone,
 5 diflucortolone, diflunisal, difluprednate, dihydrocodeine, dihydrocodeinone enol
 acetate, dihydromorphine, dihydroxyaluminum acetylsalicylate, dimenoxadol,
 dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone,
 diprocetyl, dipyrone, ditazol, droxicam, emorfazone, enfenamic acid, enoxolone,
 epirizole, eptazocine, etersalate, ethenzamide, ethoheptazine, ethoxazene,
 10 ethylmethylthiambutene, ethylmorphine, etodolac, etofenamate, etonitazene,
 etoricoxib, eugenol, felbinac, fenbufen, fenclozic acid, fendosal, fenoprofen,
 fentanyl, fentiazac, fepradinol, feprazone, floctafenine, fluazacort, flucloronide,
 flufenamic acid, flumethasone, flunisolide, flunixin, flunoxaprofen, fluocinolone
 acetoneide, fluocinonide, fluocortin butyl, fluocortolone, fluoresone,
 15 fluorometholone, fluperolone, flupirtine, fluprednidene, fluprednisolone,
 fluproquazone, flurandrenolide, flurbiprofen, formocortal, fosfosol, gentisic acid,
 glafenine, glucametacin, glycol salicylate, guaiazulene, halcinonide,
 halometasone, haloprednone, hydrocodone, hydrocortamate, hydrocortisone,
 hydromorphone, hydroxypethidine, ibufenac, ibuprofen, ibuproxam, imidazole
 20 salicylate, indomethacin, indoprofen, isofezolac, isoladol, isomethadone, isonixin,
 isoxepac, isoxicam, ketobemidone, ketoprofen, ketorolac, *p*-lactophenetide,
 lefetamine, levorphanol, lofentanil, lonazolac, lornoxicam, loxoprofen, lysine
 acetylsalicylate, mazipredone, meclofenamic acid, medrysone, mefenamic acid,
 meperidine, meprednisone, meptazinol, mesalamine, metazocine, methadone,
 25 methotrimeprazine, methylprednisolone, metiazinic acid, metofoline, metopon,
 mofebutazone, mofezolac, morazone, morphine, morphine hydrochloride,
 morphine sulfate, morpholine salicylate, myrophine, nabumetone, nalbuphine,
 1-naphthyl salicylate, naproxen, narceine, nefopam, nicomorphine, nifenazone,
 niflumic acid, nimesulide, 5'-nitro-2'-propoxyacetanilide, norlevorphanol,
 30 normethadone, normorphine, norpipanone, olsalazine, opium, oxaceprol,
 oxametacine, oxaprozin, oxycodone, oxymorphone, oxyphenbutazone,
 papaveretum, paramethasone, paranyline, parecoxib, parsalmide, pentazocine,

perisoxal, phenacetin, phenadoxone, phenazocine, phenazopyridine
hydrochloride, phenocoll, phenoperidine, phenopyrazone, phenyl acetylsalicylate,
phenylbutazone, phenyl salicylate, phenyramidol, piketoprofen, piminodine,
pipebuzone, piperylone, pirofen, pirazolac, piritramide, piroxicam, pranoprofen,
5 prednicarbate, prednisolone, prednisone, prednival, prednylidene, proglumetacin,
proheptazine, promedol, propacetamol, propiram, propoxyphene,
propyphenazone, proquazone, protizinic acid, proxazole, ramifenazone,
remifentanil, rimazolium metilsulfate, rofecoxib, salacetamide, salicin,
salicylamide, salicylamide *o*-acetic acid, salicylic acid, salicylsulfuric acid,
10 salsalate, salverine, simetride, sufentanil, sulfasalazine, sulindac, superoxide
dismutase, suprofen, suxibuzone, talniflumate, tenidap, tenoxicam, terofenamate,
tetrandrine, thiazolinobutazone, tiaprofenic acid, tiaramide, tilidine, tinoridine,
tixocortol, tolfenamic acid, tolmetin, tramadol, triamcinolone, tropesin,
valdecoxib, viminol, xenbucin, ximoprofen, zaltoprofen and zomepirac.


- 15 18. The tablet of Claim 16 wherein the analgesic, antipyretic or anti-inflammatory agent is a selective COX-2 inhibitory drug.
19. The tablet of Claim 18 wherein the selective COX-2 inhibitory drug is a compound having the formula



- 20 where R^{15} is a methyl, amino or imide group, R^{16} is hydrogen or a C_{1-4} alkyl or alkoxy group, X is N or CR^{17} where R^{17} is hydrogen or halogen, and Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a five- to six-membered ring that is unsubstituted or substituted at one or more positions with oxo, halo, methyl or halomethyl groups.
- 25 20. The tablet of Claim 18 wherein the selective COX-2 inhibitor is selected from the group consisting of celecoxib, deracoxib, valdecoxib, parecoxib, rofecoxib,


etoricoxib, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one, (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid, 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methyl-1-butyloxy)-5-[4-(methylsulfonyl)phenyl]-3-(2H)-pyridazinone and salts thereof.

- 5 21. The tablet of Claim 3 wherein the drug is an agent useful in treatment and/or prevention of sexual dysfunction.
22. The tablet of Claim 21 wherein the agent is selected from the group consisting of PDE5 inhibitors, cyclic AMP activators, α -adrenergic antagonists and dopaminergic agonists.
- 10 23. The tablet of Claim 21 wherein the agent is a compound of formula



or a pharmaceutically acceptable salt thereof, wherein

- R^1 , R^2 and R^3 are the same or different and are H, C_{1-6} alkyl (optionally phenyl substituted), C_{3-5} alkenyl or alkynyl or C_{3-10} cycloalkyl, or where R^3 is as above and R^1 and R^2 are cyclized with the attached N atom to form pyrrolidinyl, piperidinyl, morpholinyl, 4-methylpiperazinyl or imidazolyl groups;
- 15 X is H, F, Cl, Br, I, OH, C_{1-6} alkyl or alkoxy, CN, carboxamide, carboxyl or (C_{1-6} alkyl)carbonyl;
- 20 A is CH, CH_2 , CHF, CHCl, CHBr, CHI, $CHCH_3$, C=O, C=S, CSCH₃, C=NH, CNH₂, CNHCH₃, CNHCOOCH₃, CNHCN, SO₂ or N;
- B is CH, CH_2 , CHF, CHCl, CHBr, CHI, C=O, N, NH or NCH₃, and n is 0 or 1; and
- D is CH, CH_2 , CHF, CHCl, CHBr, CHI, C=O, O, N, NH or NCH₃.
- 25 24. The tablet of Claim 21 wherein the agent is a compound of formula



wherein X is O or S, or a pharmaceutically acceptable salt thereof.

25. The tablet of Claim 1 that is suitable for peroral administration.
26. The tablet of Claim 1 that is suitable for intraoral administration.
- 5 27. The tablet of Claim 1 wherein the coating is present in an amount representing a weight gain of about 0.1% to about 5%.
28. The tablet of Claim 1 wherein the gellan gum constitutes about 25% to 100% by weight of the coating.
29. The tablet of Claim 1 wherein the gellan gum constitutes about 50% to 100% by
10 weight of the coating.
30. The tablet of Claim 1 wherein the coating further comprises at least one additional excipient selected from the group consisting of buffering agents, plasticizers and dispersing and emulsifying agents.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 August 2003 (14.08.2003)

PCT

(10) International Publication Number
WO 03/066030 A3

- (51) International Patent Classification⁷: **A61K 9/34**
- (21) International Application Number: **PCT/US03/03837**
- (22) International Filing Date: 6 February 2003 (06.02.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/355,705 7 February 2002 (07.02.2002) US
- (71) Applicant (*for all designated States except US*): **PHARMACIA CORPORATION** [US/US]; Global Patent Department, 575 Maryville Centre Drive - 5th Floor, Mail Zone 1006, St. Louis, MO 63141 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **MARTINO, Alice, C.** [US/US]; 6232 Far Hills Way, Kalamazoo, MI 49009 (US). **NOACK, Robert, M.** [US/US]; 1134 Iroquois Drive S.E., Grand Rapids, MI 49506 (US). **PIERMAN, Steven, A.** [US/US]; 7608 Harvest Lane, Portage, MI 49002 (US).
- (74) Agents: **FORBES, James, C. et al.**; Pharmacia Corporation, Global Patent Department, P.O. Box 1027, St. Louis, MO 63006 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- (88) Date of publication of the international search report:
16 October 2003
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 03/066030 A3

(54) Title: **PHARMACEUTICAL TABLET**

(57) Abstract: A pharmaceutical tablet is provide comprising a core and a coating adherent thereto, wherein (a) the core comprises solid particles of a water-soluble dye distributed in a matrix, and (b) the coating comprises gellan gum. The tablet is suitable for peroral or intraoral administration, for example for delivery of a drug contained in the core of the tablet to a subject. The tablet has a speckled appearance that renders the tablet readily identifiable.

INTERNATIONAL SEARCH REPORT

Internat Application No

PCT/US 03/03837

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K9/34

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 01 26634 A (MONSANTO COMPANY) 19 April 2001 (2001-04-19) page 35 -page 36; example 12.13 ----	1-30
A	US 6 113 945 A (JACOBS ET AL.) 5 September 2000 (2000-09-05) column 2, line 62 -column 3, line 39 ----	1-30
A	WO 94 18953 A (WARNER-JENKINSON COMPANY, INC.) 1 September 1994 (1994-09-01) page 1 -----	1-30

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search

21 July 2003

Date of mailing of the international search report

31/07/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Benz, K

INTERNATIONAL SEARCH REPORT
In relation on patent family members

International Application No
PCT/US 03/03837

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0126634	A	19-04-2001	US 6485747 B1	26-11-2002
			AU 8008400 A	23-04-2001
			EP 1220660 A1	10-07-2002
			WO 0126634 A1	19-04-2001
<hr/>				
US 6113945	A	05-09-2000	NONE	
<hr/>				
WO 9418953	A	01-09-1994	US 5411746 A	02-05-1995
			AT 237317 T	15-05-2003
			AU 682843 B2	23-10-1997
			AU 5802294 A	14-09-1994
			CA 2156855 A1	01-09-1994
			DE 69332888 D1	22-05-2003
			EP 0686031 A1	13-12-1995
			JP 8509997 T	22-10-1996
			WO 9418953 A1	01-09-1994
			US 5512314 A	30-04-1996
			US 5595592 A	21-01-1997

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.